Spun out of University of Côte d’Azur and Inserm, InnoSkel expects to fund clinical work to address a form of skeletal dysplasia that causes dwarfism.

InnoSkel, a France-based gene therapy spinout of University of Côte d’Azur and research institute Inserm targeting rare skeletal diseases, publicly launched today with €20m ($24.3m) of series A capital. The round was co-led by life sciences-focused investment firm Vida Ventures and private equity firm Jeito Capital with participation from EU-backed regional investment fund Région Sud…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.